63.62
-2.09%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $7.63bn
- Last close × shares
- Volume
- 1.1m
- Shares, 20 Nov 2026
- Price to earnings
- 95.4
About Corcept Therapeutics
From its filings with the US Securities and Exchange Commission
Corcept Therapeutics is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CORT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $761.4m and net income of $99.7m. At that date it held total assets of $836.7m and shareholders' equity of $647.8m.
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia. Excessive cortisol activity, known as hypercortisolism, may lead to hypertension, diabetes, impaired glucose tolerance, obesity, fatty liver disease, depressed mood, psychosis, wasting of the arms and legs, edema, fatigue, insomnia and other problems.
Cortisol reduces a patient’s immune response to oncogenesis, shields certain cancer cells from the apoptotic effects of chemotherapy and facilitates the growth of others. Pre-clinical and clinical data indicate that modulating cortisol activity may improve outcomes in patients with fatty liver disease and metabolic dysfunction-associated steatohepatitis (“MASH”), which are precursors of liver fibrosis and cirrhosis. Pre-clinical and clinical data also suggest that modulating cortisol activity may lead to treatments for patients with amyotrophic lateral sclerosis (“ALS”).
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Latest on Corcept Therapeutics
Our reporting
- Corcept Therapeutics falls 2.09% in Friday's session
- Corcept Therapeutics falls 4.15% in Thursday's session
- Corcept Therapeutics falls 3.25% in Wednesday's session
- Corcept Therapeutics falls 5.10% in Monday's session
- Corcept Therapeutics falls 2.24% in Tuesday's session
- Corcept Therapeutics rises 3.10% in Monday's session
Next results
Due on 23 Feb 2027. Analysts expect earnings of 1.12 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Corcept Therapeutics's ticker?
Corcept Therapeutics trades as CORT on its US listing, under ISIN US2183521028.
What was Corcept Therapeutics's last closing price?
63.62 on 20 Nov 2026. The figure is in USD and is never converted.
When does Corcept Therapeutics next report results?
Results are expected on 23 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.